Samsung Bioepis Nudges Closer To Ranibizumab Approvals With New Data
Similarity Data To Be Presented At 2021 ARVO Meeting
Samsung Bioepis has been tight-lipped on the potential to win approval for its SB11 biosimilar ranibizumab product this year, though new similarity data is a further positive omen for the Korea-based biosimilar player.
You may also be interested in...
Samsung Bioepis Scoops First EU Lucentis Biosimilar As 2022 Date Looms
Samsung Bioepis has seen a positive opinion in the EU for its Byooviz (ranibizumab) biosimilar treatment for wet age-related macular degeneration turned into final approval by the European Commission. The company is also leading the pack in the US.
Samsung Bioepis Backed By EMA For First Lucentis Biosimilar
Samsung Bioepis is set to make waves with the first ophthalmic biosimilar after the European regulator recommended that its ranibizumab biosimilar Byooviz receive a pan-European marketing authorization.
Xbrane Sets Cash Target Ahead Of Lucentis Ambitions In 2022
Swedish developer Xbrane Biopharma has identified a timeline to turn its cash flows positive, with plans to roll-out biosimilar Lucentis next year.